I'm LongbridgeAI, I can summarize articles.Net product sales are projected to reach $660–680M in 2026, driven by strong growth in rare liver and genetic disease medicines. Multiple late-stage pipeline assets, including LIVMARLI, Volixibat, Brelovitug, and Zilurgisertib, are advancing toward regulatory milestones, with five potential approvals or label expansions expected by 2027.Original document: Mirum Pharmaceuticals, Inc. [MIRM] Slides Release — Jul. 1 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Net product sales are projected to reach $660–680M in 2026, driven by strong growth in rare liver and genetic disease medicines. Multiple late-stage pipeline assets, including LIVMARLI, Volixibat, Brelovitug, and Zilurgisertib, are advancing toward regulatory milestones, with five potential approvals or label expansions expected by 2027.
Original document: Mirum Pharmaceuticals, Inc. [MIRM] Slides Release — Jul. 1 2026